Latest Articles
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without RT for Newly Diagnosed, High-Risk Endometrial Cancer: Results in DMMR Tumors - Medpage Today
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without RT for Newly Diagnosed, High-Risk Endometrial Cancer: Results in DMMR Tumors Medpage Today
Published: Dec. 18, 2024, 8:16 p.m.
Brian Slomovitz on Adjuvant Pembrolizumab/Chemotherapy for Advanced Endometrial Cancer - Medpage Today
Brian Slomovitz on Adjuvant Pembrolizumab/Chemotherapy for Advanced Endometrial Cancer Medpage Today
Published: Dec. 18, 2024, 3:27 p.m.
Management of Endometriosis-Related Pain: Comparing the Effectiveness of Hormonal Therapy, Surgical Interventions, and Complementary Therapies - Cureus
Management of Endometriosis-Related Pain: Comparing the Effectiveness of Hormonal Therapy, Surgical Interventions, and Complementary Therapies Cureus
Published: Dec. 12, 2024, 2:19 p.m.
Catamenial Pneumothorax in a Patient Undergoing Low-Dose Estrogen-Progestin Therapy: A Case Report - Cureus
Catamenial Pneumothorax in a Patient Undergoing Low-Dose Estrogen-Progestin Therapy: A Case Report Cureus
Published: Dec. 11, 2024, 1:59 p.m.
Top Gynecologic Cancer Research of 2024 - Cancer Therapy Advisor
Top Gynecologic Cancer Research of 2024 Cancer Therapy Advisor
Published: Dec. 9, 2024, 3 p.m.
Immunotherapy Redefines Standard of Care for Frontline Advanced Endometrial Cancer - OncLive
Immunotherapy Redefines Standard of Care for Frontline Advanced Endometrial Cancer OncLive
Published: Dec. 5, 2024, 7:04 p.m.
NMPA greenlights new endometrial cancer therapy - Investing.com India
NMPA greenlights new endometrial cancer therapy Investing.com India
Published: Dec. 4, 2024, 1:01 a.m.
Innovent & HUTCHMED Win China Approval for Breakthrough Endometrial Cancer Therapy | IVBIY Stock News - StockTitan
Innovent & HUTCHMED Win China Approval for Breakthrough Endometrial Cancer Therapy | IVBIY Stock News StockTitan
Published: Dec. 4, 2024, 12:01 a.m.
Innovent & HUTCHMED Win China Approval for Breakthrough Endometrial Cancer Therapy | HCM Stock News - StockTitan
Innovent & HUTCHMED Win China Approval for Breakthrough Endometrial Cancer Therapy | HCM Stock News StockTitan
Published: Dec. 4, 2024, midnight
Elagolix with add-back therapy found effective and tolerable for endometriosis pain - Contemporary Obgyn
Elagolix with add-back therapy found effective and tolerable for endometriosis pain Contemporary Obgyn
Published: Dec. 3, 2024, 6:36 p.m.
Link copied to clipboard!